{"title":"Early memory impairment is accompanied by changes in GluA1/p-GluA1 in APP/PS1 mice.","authors":"Ya-Bo Zhao, Xue-Fei Hou, Xin Li, Li-Su Zhu, Jing Zhu, Guo-Rui Ma, Yu-Xuan Liu, Yu-Can Miao, Qian-Yu Zhou, Lin Xu, Qi-Xin Zhou","doi":"10.2174/1567205020666221019124543","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Exploring the neurobiological mechanisms of early AD damage Background: The early diagnosis of Alzheimer's disease (AD) has a very important impact on the prognosis of AD. However, the early symptoms of AD are not obvious and difficult to diagnose. Existing studies have rarely explored the mechanism of early AD. AMPARs are early important learning memory-related receptors. However, it is not clear how the expression levels of AMPARs change in early AD.</p><p><strong>Objective: </strong>We explored learning memory abilities and AMPAR expression changes in APP/PS1 mice at 4 months, 8 months, and 12 months.</p><p><strong>Method: </strong>We used the classic Morris water maze to explore the learning and memory impairment of APP/PS1 mice and used western blotting to explore the changes in AMPARs in APP/PS1 mice.</p><p><strong>Result: </strong>We found that memory impairment occurred in APP/PS1 mice as early as 4 months of age, and the impairment of learning and memory gradually became serious with age. The changes in GluA1 and p-GluA1 were most pronounced in the early stages of AD in APP/PS1 mice.</p><p><strong>Conclusion: </strong>Our study found that memory impairment in APP/PS1 mice could be detected as early as 4 months of age, and this early injury may be related to GluA1.</p>","PeriodicalId":10810,"journal":{"name":"Current Alzheimer research","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2022-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Alzheimer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1567205020666221019124543","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: Exploring the neurobiological mechanisms of early AD damage Background: The early diagnosis of Alzheimer's disease (AD) has a very important impact on the prognosis of AD. However, the early symptoms of AD are not obvious and difficult to diagnose. Existing studies have rarely explored the mechanism of early AD. AMPARs are early important learning memory-related receptors. However, it is not clear how the expression levels of AMPARs change in early AD.
Objective: We explored learning memory abilities and AMPAR expression changes in APP/PS1 mice at 4 months, 8 months, and 12 months.
Method: We used the classic Morris water maze to explore the learning and memory impairment of APP/PS1 mice and used western blotting to explore the changes in AMPARs in APP/PS1 mice.
Result: We found that memory impairment occurred in APP/PS1 mice as early as 4 months of age, and the impairment of learning and memory gradually became serious with age. The changes in GluA1 and p-GluA1 were most pronounced in the early stages of AD in APP/PS1 mice.
Conclusion: Our study found that memory impairment in APP/PS1 mice could be detected as early as 4 months of age, and this early injury may be related to GluA1.
目的:探索阿尔茨海默病早期损害的神经生物学机制 背景:阿尔茨海默病(AD)的早期诊断对其预后有着非常重要的影响:阿尔茨海默病(AD)的早期诊断对其预后有着非常重要的影响。然而,阿尔茨海默病的早期症状并不明显且难以诊断。现有研究很少探讨早期 AD 的发病机制。AMPARs是早期重要的学习记忆相关受体。然而,AMPARs的表达水平在早期AD中如何变化尚不清楚:我们探讨了APP/PS1小鼠在4个月、8个月和12个月时的学习记忆能力和AMPAR的表达变化:方法:我们使用经典的莫里斯水迷宫来探讨APP/PS1小鼠的学习记忆障碍,并使用Western印迹来探讨APP/PS1小鼠AMPARs的变化:结果:我们发现APP/PS1小鼠早在4月龄时就出现了记忆障碍,并且随着年龄的增长,学习记忆障碍逐渐严重。结论:我们的研究发现,APP/PS1小鼠在4月龄时就出现了记忆障碍,随着年龄的增长,学习和记忆障碍逐渐严重,GluA1和p-GluA1的变化在APP/PS1小鼠AD的早期阶段最为明显:结论:我们的研究发现,APP/PS1小鼠的记忆损伤最早可在4月龄时发现,这种早期损伤可能与GluA1有关。
期刊介绍:
Current Alzheimer Research publishes peer-reviewed frontier review, research, drug clinical trial studies and letter articles on all areas of Alzheimer’s disease. This multidisciplinary journal will help in understanding the neurobiology, genetics, pathogenesis, and treatment strategies of Alzheimer’s disease. The journal publishes objective reviews written by experts and leaders actively engaged in research using cellular, molecular, and animal models. The journal also covers original articles on recent research in fast emerging areas of molecular diagnostics, brain imaging, drug development and discovery, and clinical aspects of Alzheimer’s disease. Manuscripts are encouraged that relate to the synergistic mechanism of Alzheimer''s disease with other dementia and neurodegenerative disorders. Book reviews, meeting reports and letters-to-the-editor are also published. The journal is essential reading for researchers, educators and physicians with interest in age-related dementia and Alzheimer’s disease. Current Alzheimer Research provides a comprehensive ''bird''s-eye view'' of the current state of Alzheimer''s research for neuroscientists, clinicians, health science planners, granting, caregivers and families of this devastating disease.